Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Nevro is raising its adjusted EBITDA guidance for the full-year 2024 to a range of negative $5 million to positive $2 million from its previous guidance range of negative $14 million to negative $8 million.
For the second quarter of 2024, the company expects worldwide revenue to be in the range of approximately $106 million to $108 million and adjusted EBITDA to be in the range of negative $3.5 million to negative $2.5 million.
Posted In: NVRO